HHS announced last week
that John O’Brien will succeed the late Dan Best in heading the agency’s prescription drug pricing reform efforts. O’Brien, a former health insurance executive, will serve as senior adviser for drug pricing reform to HHS Secretary Alex Azar. He will lead HHS’ effort to implement the administration’s recent proposal to drive down prescription drug rates paid by Medicare Part B by indexing them to the much lower prices paid by other advanced countries and changing the way physicians are paid for administering those drugs. The move is estimated to save more than $17 billion over five years.